Genomic profiling of pancreatic islets in non-diabetic and diabet

Genomic profiling of pancreatic islets in non-diabetic and diabetic states is needed in order to dissect the contribution of epigenetic mechanisms to the declining proliferation potential of beta cells that we see with aging or the beta-cell failure observed in diabetes.

In-depth understanding of epigenetic landscapes can help to improve protocols for in vitro differentiation towards the fate, enhance beta-cell proliferation, and lead to the discovery of novel therapeutic targets.”
“Aims: A recent study that evaluated 22 methods for enumerating faecal indicator bacteria in sand recommended standardization to a preferred method, but all researchers involved in that study had extensive experience in processing sand samples. The purpose of this study PF-573228 concentration was to evaluate how well the recommended learn more method can be transferred to laboratories without such experience.

Methods and Results: Eight southern California laboratories that rarely measure bacteria in sand processed six sand and three water samples in replicates to assess repeatability. Among-laboratory variability was found to be less than within-laboratory variability, with no significant differences in results among any of the laboratories. Moreover, within-laboratory

variability was comparable between the sand and water samples, indicating that the elution procedure added little additional method error even when performed by laboratories without prior experience.

Conclusions: The simple extraction method for enumerating Enterococcus in beach sands was easily transferable to and repeatable among laboratories with little or no prior experience.

Significance and Impact of the Study: The demonstrated success of technology transfer will further demonstrate the success of method standardization and adoption, aiding in understanding of how sands affect surface water quality.”
“Objective: To characterize the co-existence of multiple pain-related complaints in patients enrolled in a series of pharmaceutical company drug

trials for the treatment of Major Depressive Disorder (MDD). Method: Pooled ‘blinded’ data from 2191 patients enrolled in randomized, Selleckchem MX69 Multicenter, double-blind placebo-controlled studies for the treatment of MDD were analyzed. Painful symptoms were assessed using the seven pain symptoms subset of the Somatic Symptoms Inventory: ‘Headache,’ ‘Pain in lower back,’ ‘Neck pain,’ ‘Pain in joints,’ ‘Soreness in muscles,’ ‘Pain in heart or chest,’ and ‘Pain or cramps in abdomen.’ The 17-item Hamilton Depression Rating Scale (HAMD) was used to assess severity of depression. Results: Of those meeting the study entry criteria (total HAMD score >= 15), 25% reported no pain complaints and 18% reported 1 pain compliant; the majority (57%) of patients reported the co-existence of multiple pain-related complaints, with 14%, 12%, 11%, 11%, 7%, and 3% of patients reporting 2, 3, 4, 5, 6 and 7 different pain symptoms, respectively.

Comments are closed.